181 related articles for article (PubMed ID: 12866287)
1. [SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].
MMW Fortschr Med; 2003 May; 145(22):57. PubMed ID: 12866287
[No Abstract] [Full Text] [Related]
2. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
[No Abstract] [Full Text] [Related]
3. [Evidence of raloxifene on postmenopausal osteoporosis].
Okano H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
[No Abstract] [Full Text] [Related]
4. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
5. [Raloxifene (Celvista, Evista)].
Body JJ; Sternon J
Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
[TBL] [Abstract][Full Text] [Related]
6. [Effects of raloxifene on bone loss and fracture risk in the menopausal woman].
Vignot E; Meunier PJ
Contracept Fertil Sex; 1999 Dec; 27(12):858-60. PubMed ID: 10676043
[TBL] [Abstract][Full Text] [Related]
7. [Raloxifene hydrochloride].
Itabashi A
Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
[No Abstract] [Full Text] [Related]
8. Reduction of vertebral fracture risk with raloxifene.
Bashore R
J Fam Pract; 1999 Nov; 48(11):911-2. PubMed ID: 10907630
[No Abstract] [Full Text] [Related]
9. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
Inaba M
Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
11. Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.
Thiebaud D
J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S124-5. PubMed ID: 21213508
[No Abstract] [Full Text] [Related]
12. Does raloxifene reduce risk of vertebral fractures? Is this another, brighter way to treat osteoporosis?
Hathirat S; Evans MF
Can Fam Physician; 2001 Oct; 47():1982-4. PubMed ID: 11723592
[No Abstract] [Full Text] [Related]
13. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
14. Fewer fractures with raloxifene.
Feinberg AW
Health News; 1999 Oct; 5(12):3. PubMed ID: 10536528
[No Abstract] [Full Text] [Related]
15. [Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis].
MMW Fortschr Med; 2004 Mar; 146(10):46. PubMed ID: 15347088
[No Abstract] [Full Text] [Related]
16. Another selective estrogen-receptor modulator for osteoporosis.
Becker C
N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
[No Abstract] [Full Text] [Related]
17. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene remains an option.
MacIver DW
Can Fam Physician; 2002 Apr; 48():679; author reply 679-80. PubMed ID: 12046354
[No Abstract] [Full Text] [Related]
19. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
Qu Y; Wong M; Thiebaud D; Stock JL
Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
[TBL] [Abstract][Full Text] [Related]
20. [Selective estrogen receptor modulators (SERMs)].
Matsumoto T
Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
